comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-13 15:17:02 Page View：793

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA panel endorses Alnylam’s heart drug — after picking it apart
Next article： In age of alternative facts, a scholarly course on calling out crap

focus

Dobbs anniversary: the lost opportunity of abortion as health care

NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

PEPFAR is under serious threat — and so is global health

AhospitalinNairobi,Kenya,thatisabeneficiaryoftheglobalhealthinitiativePEPFAR.BrentStirton/GettyImage

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

With fresh data, a dynamic duo powers Eli Lilly to new heights

EliLillyCEODavidRicks(left)andChiefScientificOfficerDanielS.SkovronskyMollyFergusonforSTATThepartner

comprehensive

explore

focus

With fresh data, a dynamic duo powers Eli Lilly to new heights